October 4th 2021

CARE scientists identified a SARS-CoV-2 neutralizing antibody with activity against all known variants of concern

CARE scientists identified a SARS-CoV-2 neutralizing antibody with activity against all known variants of concern

One of CARE’s approach to develop therapeutics to address the COVID-19 pandemic is the discovery of virus neutralizing antibodies. With this goal, the CARE partner Centre Hospitalier Universitaire Vaudois screened B cells from COVID-19 donors and identifyed P5C3, a highly potent and broadly neutralizing monoclonal antibody with activity against all SARS-CoV-2 variants of concern that are known to date.

The research findings suggest that P5C3 is a promissing candidate as a prophylactic agent in  immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2 infected individuals.

To learn more, read the article in Cell Reports: A highly potent antibody effective against SARS-CoV-2 variants of concern.